TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,518,058 | -4.7% | 1,512,087 | +63.7% | 0.00% | 0.0% |
| Q2 2023 | $14,190,965 | -20.3% | 923,891 | +16.8% | 0.00% | -25.0% |
| Q1 2023 | $17,794,717 | -68.0% | 791,228 | -70.0% | 0.00% | -66.7% |
| Q4 2022 | $55,522,270 | -11.8% | 2,640,146 | +3.4% | 0.01% | -20.0% |
| Q3 2022 | $62,930,000 | -0.6% | 2,553,974 | -2.2% | 0.02% | +7.1% |
| Q2 2022 | $63,305,000 | -5.2% | 2,612,646 | +0.9% | 0.01% | 0.0% |
| Q1 2022 | $66,747,000 | -17.1% | 2,590,107 | -0.1% | 0.01% | -12.5% |
| Q4 2021 | $80,510,000 | +203.7% | 2,593,757 | +137.2% | 0.02% | +166.7% |
| Q3 2021 | $26,513,000 | -26.0% | 1,093,322 | -55.5% | 0.01% | -25.0% |
| Q2 2021 | $35,852,000 | +73.5% | 2,457,280 | +197.0% | 0.01% | +60.0% |
| Q1 2021 | $20,661,000 | +6.2% | 827,434 | +15.9% | 0.01% | 0.0% |
| Q4 2020 | $19,459,000 | – | 713,966 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |